QUOTE AND NEWS
Benzinga  Jun 6  Comment 
Goldman Sachs’ Stephan Stewart believes Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) could have 26 percent upside. Stewart initiated coverage of the company with a Buy rating and price target of $196. Reasons to Own...
Motley Fool  Jun 4  Comment 
Jazz Pharmaceuticals has agreed to buy the clinical-stage drug developer in a $1.5 billion deal.
Motley Fool  May 31  Comment 
Bruce Kovner and Israel Englander's funds were among those that might have benefited from a 70% spike in Celator Pharmaceuticals stock today. Given the move higher, it might pay off to know what other biotech stocks these two funds have been buying.
Forbes  May 6  Comment 
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ebix Inc (NASD: EBIX), where a total of 1,715 contracts have traded so far, representing approximately 171,500 underlying shares. That...
Motley Fool  May 3  Comment 
These two catalysts -- one far more important than the other -- provided the sparks for Jazz last month.
Benzinga  Mar 31  Comment 
The US FDA granted marketing approval for Defitelio® [defibrotide sodium] for the treatment of adult and pediatric patients with hepatic VOD, also known as sinusoidal obstruction syndrome [SOS], with renal or pulmonary dysfunction following HSCT....
newratings.com  Mar 3  Comment 
SOUTH SAN FRANCISCO (dpa-AFX) - Auris Medical Holding AG (EARS) has completed patient enrollment in its phase III clinical trial of AM-101 in acute inner ear tinnitus. In the trial, dubbed TACTT2, which is being conducted primarily in...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki